

January 31, 2023

Notice Concerning the Establishment of “Ono Pharma Oncology, Immunology, Neurology Research Foundation,” a General Incorporated Foundation

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “ONO”) announced that it established Ono Pharma Oncology, Immunology, Neurology Research Foundation, a General Incorporated Foundation (“New Foundation”) for the purpose of contribution to academia on January 26, 2023 and today resolved to contribute a fund necessary for commencement of a research grant project.

Under the corporate philosophy of “Dedicated to the Fight against Disease and Pain,” ONO has considered the creation of innovative drugs to be one of its material issues that we should address, and designated the areas of oncology, immunology and neurology as priority areas for research and development. ONO has been keeping on the challenge to discover and develop more unique and innovative drugs by actively promoting open innovation as its strength.

The New Foundation supports basic research in medicinal and pharmaceutical areas aiming at “contribution to the health of people in the world by supporting cutting edge science and researchers leading to innovative (breakthrough) research achievements.” The new research achievements from these activities will lead to contribution to the health of people in the world, which is consistent with our corporate philosophy. We believe that these activities will serve our sustainable growth and enhancement of our corporate value from a medium- to long-term perspective, in which we contribute to the health of people around the world through the progress of research in the medicinal and pharmaceutical fields.

1. Purpose of New Foundation

We aim to contribute to the health of people in the world by supporting cutting edge science and researchers leading to innovative (breakthrough) research achievements in the oncology, immunology and neurology areas in which high unmet medical needs still remain.

2. Outline of New Foundation

Name	Ono Pharma Oncology, Immunology, Neurology Research Foundation
Address	2-1-5 Doshomachi, Chuo-ku, Osaka
Activities	(1) Provision of grants for researchers in oncology, immunology and neurology areas (2) Other necessary activities to achieve the purpose of New Foundation
Established	January 2023
Representative Director	Hiroshi AWATA
Officers at establishment	Councilor: Shizuo AKIRA, Hideyuki OKANO, Kohei MIYAZONO, Toichi TAKINO Director: Masashi AOKI, Shuichi KOIZUMI, Hideyuki SAYA, Kiyoshi TAKEDA, Hiroyuki MANO, Akihiko YOSHIMURA, Hiroshi AWATA Auditor: Seichiro AZUMA, Keiko TAKASE

An impact of this matter on our business results for the current fiscal year ending March, 2023 would be marginal. Should there be any events to be disclosed in the future, we will announce them in a timely manner.

Contact:

Ono Pharmaceutical Co., Ltd.

Corporate Communications

public_relations@ono-pharma.com